Immunocore attracts Lilly in co-co deal
This article was originally published in Scrip
Immunocore has locked in its fourth big pharma partner in just over a year – Lilly. Unlike previous deals, Immunocore has managed to retain some co-discovery and co-development rights, making it unique among the company's collaborations. This is likely to be the UK biotech's last deal for a while.
You may also be interested in...
Eli Lilly & Co. did not rush into the immuno-oncology game like its big pharma peers, but the acquisition of newly public ARMO gives the company its most advanced IO asset via external innovation – an increased focus for Lilly's portfolio.
China's WuXi PharmaTech, an R&D technology company serving the pharmaceutical, biotechnology and medical device industries, has announced construction of a new manufacturing facility in Philadelphia, US designed for cell therapy products, including chimeric antigen receptor T-cell (CAR-T) therapies. More manufacturing power is crucial to the success of this burgeoning, high-potential field.
Takeda has managed to persuade NICE, the health technology appraisal institute for England and Wales, to recommend its ulcerative colitis drug Entyvio (vedolizumab) without the restrictions the institute had previously stipulated – as long as the company offers a discount via a patient access scheme.